Table 3.
Characteristics | Successful outcome n (%) |
Unsuccessful outcome n (%) |
Crude OR (95% CI) |
Adjusted OR (95% CI) |
Adjusted P value |
---|---|---|---|---|---|
Age (years) | |||||
≤40 | 63 (78.8) | 17 (21.2) | 1 | 1 | |
>40 | 20 (69.0) | 9 (31.0) | 1.7 (0.6–4.3) | 1.4 (0.5–3.8) | 0.56 |
Gender | |||||
Female | 40 (76.9) | 12 (23.1) | 1 | 1 | |
Male | 43 (75.4) | 14 (24.6) | 1.08 (0.5–2.6) | 1.3 (0.5–3.5) | 0.56 |
Facility | |||||
Public | 21 (67.7) | 10 (32.3) | 1.9 (0.7–4.7) | 4.5 (1.2–16.7) | 0.023 |
Private | 62 (79.5) | 16 (20.5) | 1 | 1 | |
Treatment category | |||||
New | 78 (76.5) | 24 (23.5) | 1 | 1 | |
Previously treated | 5 (71.4) | 2 (28.6) | 1.3 (0.2–7.1) | 1.8 (0.3–11.1) | 0.54 |
Type of TB | |||||
Pulmonary | 80 (75.5) | 26 (24.5) | |||
Extrapulmonary | 3 (100.0) | 0.0 | — | — | — |
Anti-TB regimen | |||||
Regimen 1 | 50 (74.6) | 17 (25.4) | 1.3 (0.5–3.1) | 1.2 (0.4–3.7) | 0.74 |
Regimen 2 | 33 (78.6) | 9 (21.4) | 1 | 1 | |
Received ART | |||||
Yes | 31 (83.8) | 6 (16.2) | 1 | 1 | |
No | 52 (72.2) | 20 (27.8) | 2.0 (0.7–5.5) | 7.0 (1.3–36.8) | 0.021 |
Received CPT | |||||
Yes | 45 (77.6) | 13 (22.4) | 1 | 1 | |
No | 38 (74.5) | 13 (25.5) | 1.2 (0.5–2.9) | 1.4 (0.5–4.4) | 0.53 |
Regimen 1: 2RHZE/6EH; regimen 2: 2RHZE/4RH (R: rifampicin, H: isoniazid, Z: pyrazinamide, and E: ethambutol); OR: odds ratio; ART: antiretroviral therapy; TB: tuberculosis; HIV: human immunodeficiency virus; CPT: cotrimoxazole preventive therapy.